Europe's largest "green" methanol plant opened in Denmark on Tuesday, boosting the continent's emissions reduction efforts -- ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

The world's first commercial-scale e-methanol plant began operations in Denmark on Tuesday, with shipping giant Maersk set to ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to ...

The best metric is not weight, but a particularly toxic kind of fat.

ParticipACTION will kick off its search for Canada's Most Active Community with the ParticipACTION Community Challenge ...

The National Institute for Health and Care Excellence (Nice) previously stopped its appraisal of semaglutide (Wegovy) for use ...